FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.
What happened
FDA inspected Ashirwad Hospital & Research Centre in Ulhasnagar, Maharashtra, India, from May 5 to May 9, 2025, as part of its Bioresearch Monitoring Program. The inspection reviewed Dr. Chandre's conduct of an in vivo bioequivalence study of doxorubicin hydrochloride liposome injection 20 mg/10 mL (Protocol 0270-22). FDA found that informed consent was not obtained in accordance with 21 CFR part 50 because the consent form was ambiguous about whether approval and effectiveness statements applied to the test or reference product and overstated possible benefit.
What FDA found
The clinical investigator did not obtain legally effective informed consent in accordance with 21 CFR part 50.
21 CFR 312.60; 21 CFR 50.20The informed consent form used ambiguous words that did not make clear whether statements about approval and effectiveness applied to the test product or the reference product.
21 CFR 50.20The informed consent form overstated the possible benefit of the investigational product, which could unduly influence people to participate.
21 CFR 50.20
What FDA wants
FDA asks Dr. Chandre to notify CDER's Office of Scientific Investigations in writing within 15 business days of receiving the letter about actions taken to prevent similar violations. If he believes he complied, he should include his reasoning and supporting information.
Who should pay attention
- clinical research sites running FDA-regulated bioequivalence studies
- sponsors and CROs using investigator sites in India
- ethics committees and IRBs reviewing informed consent forms
This is a summary. Read the original letter on fda.gov.